Changing the Ovarian Cancer Treatment Landscape with a DNA-Mediated Immunotherapy

Episode Summary

Executive Summary: The episode centers on Immunon’s IMNN-001, a DNA-mediated IL-12 immunotherapy for newly diagnosed ovarian cancer. CEO Stacey Lindborg argues that local delivery into the peritoneal cavity can activate anti-tumor immunity without the systemic toxicities that limited earlier IL-12 approaches, citing a Phase II overall-survival advantage and an ongoing Phase III trial. The discussion also covers diagnostics, frontline ovarian-cancer care, and Immunon’s separate DNA vaccine platform.

Main Topics: Ovarian cancer burden and late diagnosis (Priority: 5/5): The conversation opens with the high mortality of ovarian cancer, the lack of early symptoms, and the absence of effective screening, which together lead to most patients being diagnosed at advanced stages. Frontline treatment landscape and unmet need (Priority: 5/5): Lindborg explains that standard-of-care surgery plus platinum chemotherapy remains the frontline approach but has not materially changed in over 25 years and still leaves most patients facing relapse and poor survival. IMNN-001 mechanism and local IL-12 delivery (Priority: 5/5): Immunon’s lead program uses a DNA construct to produce IL-12 directly in the tumor microenvironment via intraperitoneal administration, aiming to convert an immunologically 'cold' tumor environment into a 'hot' one. Safety advantages over prior IL-12 attempts (Priority: 4/5): The company emphasizes that prior systemic IL-12 efforts failed because of toxicity, whereas its localized peritoneal delivery appears to keep blood exposure low while driving strong immune activity in the tumor site. Clinical data and Phase III development (Priority: 5/5): Phase II data showed an overall-survival benefit and a stronger signal in HRD-positive patients; the company is now running Phase III with up to 17 weekly doses and a biomarker-informed strategy. Plasmid DNA vaccine platform and COVID proof-of-concept (Priority: 3/5): Lindborg also discusses a second platform for nucleic-acid vaccines, including a seasonal COVID vaccine, highlighting stability, durability, and manufacturing flexibility, while noting the company is seeking a partner for further development. Capital strategy for a small public biotech (Priority: 3/5): The interview closes with funding strategy: Immunon is conserving cash, pursuing bridge financing, and seeking long-term health-care investors to support the Phase III trial.

Key Arguments: Ovarian cancer outcomes remain poor largely because most patients are diagnosed late and there is no reliable preventative screening test. Frontline therapy has been effective but largely unchanged for decades, and most women still relapse or die of the disease. IL-12 is a biologically compelling anti-cancer cytokine, but earlier programs failed because intravenous delivery caused systemic toxicity. IMNN-001 is designed to localize IL-12 production in the tumor microenvironment, potentially preserving anti-tumor activity while avoiding severe blood-borne toxicities. The company’s Phase II results suggest a meaningful survival advantage, particularly in HRD-positive/BRCA-mutated patients. The Phase III trial is advancing with biomarker-driven focus to identify the patients most likely to benefit and to speed commercialization. Immunon’s DNA vaccine platform could offer advantages in stability, durability, and manufacturing flexibility compared with traditional and mRNA approaches. The company believes its data strength supports iterative financing even in a difficult capital market.

Data Points: Estimated U.S. ovarian cancer deaths in 2025: nearly 13,000 - Opening framing of the disease burden Patients diagnosed at advanced stage: about 80% - Lindborg explains why ovarian cancer is often caught late Five-year relative survival for advanced-stage disease: less than 30% - Prognosis discussed for women diagnosed today CA125 elevation in epithelial ovarian cancer: about 80% of cases - Used as a diagnostic marker, more reliable in late-stage disease Prior clinical attempts to harness IL-12: around 40 clinical trials - Historical context for the cytokine approach Overall-survival benefit in Phase II: 13 months - Immunon-plus-standard-of-care versus standard of care alone Hazard ratio in overall trial: 0.7 - Phase II efficacy result in the full study population Hazard ratio in HRD-positive subgroup: 0.42 - Stronger benefit among biomarker-positive patients Survival in HRD subgroup control arm: median 37 months - Comparator benchmark mentioned for the subgroup Dose range studied: 36 mg/m² to 100 mg/m² - Phase II dose-ranging and Phase III dose selection Interferon gamma increase at top dose: above 60-fold - Tumor microenvironment biomarker response at 100 mg/m² IL-12 increase at top dose: above 25-fold - Tumor microenvironment biomarker response at 100 mg/m² Blood biomarker change across doses: incredibly low / almost no change - Supports localized effect and safety Duration of IL-12 expression: several days, returning near baseline by about a week - Explains weekly dosing schedule Phase III dosing schedule: up to 17 weekly treatments - Roughly half before surgery and half after surgery Plasmid/vaccine stability at 4°C: at least 1 year - Plasmid vaccine platform storage profile Plasmid/vaccine stability at room temperature: 1 month - Plasmid vaccine platform storage profile Plasmid/vaccine stability at 37°C: at least 2 weeks - Plasmid vaccine platform storage profile Durability of vaccine response: up to 6 months - Phase I and preclinical vaccine data Neutralizing antibody titer increase at 6 months: up to 3-fold - Seasonal COVID vaccine proof-of-concept Company market cap: about $15 million - Funding discussion for Immunon as a public company Cash at end of Q2: just under $5 million - Current balance sheet context Site activation speed versus benchmark: half the time - FDA/IRB approval to first site activation compared with big pharma/global CRO benchmarks

Pivotal Quotes: "80% of patients are diagnosed in late stage" — Stacey Lindborg: On why ovarian cancer outcomes remain so poor "We see a 13-month advantage in overall survival in women who received Immunon plus the standard of care compared to those who were only receiving the standard of care." — Stacey Lindborg: Summarizing the most important Phase II efficacy result "We see a very strong dose response with IL-12 levels, interferon gamma increasing multiple fold... in blood levels, we see incredibly low and almost no change across the dose levels." — Stacey Lindborg: Describing localized immune activation with limited systemic exposure

Implications: If Phase III confirms the Phase II signal, IMNN-001 could become a rare frontline ovarian-cancer innovation with better survival and manageable safety. The DNA vaccine platform may also offer a stable, scalable approach for future infectious-disease vaccines.